
    
      The control group received docetaxel + capecitabine regimen;Experimental group received
      Nimotuzumab combined docetaxel + capecitabine regimen.The main purpose is to evaluate
      Nimotuzumab Plus Docetaxel and Capecitabine（TX）as First-Line Treatment in Patients With
      Recurrent/Metastatic triple negative breast cancer would improve objective response rate (ORR
      ) comparing with Docetaxel and Capecitabine（TX）.
    
  